IgGenix
PrivateLast Round
Series B
Feb 6, 2023
Total Funding Raised
$75M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
IgGenix operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series B round in February 2023.
IgGenix is a biotechnology company that develops an antibody-based therapeutic platform designed to accelerate clinical responses to allergies by engineering antibodies that effectively capture allergens and enhance immune modulation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IgGenix Comparables
Compare IgGenix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mabylon AG | 83% | |
| Aravax | 79% | |
| Roche Holding | 74% |
For institutional investors. Book with your work email.
IgGenix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 6, 2023 | ||||
| Series A Extension | Jul 27, 2021 | ||||
| Series A | Aug 4, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
IgGenix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AllerFund | Series A Extension, Series B |
| Medical Incubator Japan | Series B |
| Khosla Ventures | Series B, Series A, Series A Extension |
| Alexandria Venture Investments | Series A Extension, Series B |
| ShangBay Capital | Series A Extension |
| Alexandria Venture Investments | Series A Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 45% MoM, reaching 2.7K.
- Jun 17, 2026
Monthly visitors grew 36% MoM, reaching 1.8K.
For institutional investors. Book with your work email.
IgGenix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about IgGenix's valuation, stock price, and market status.
Is IgGenix a public or private company?
IgGenix is a private company.
What is the current stock price of IgGenix?
IgGenix is a private company, so its shares have no public market price. Caplight tracks IgGenix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is IgGenix worth (valuation)?
Valuation information for IgGenix is not publicly available.
Can I buy IgGenix stock?
IgGenix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was IgGenix's last funding round?
IgGenix's most recent funding round was Series B on February 6, 2023.
Who are the main investors in IgGenix?
Key investors in IgGenix include Khosla Ventures, Alexandria Venture Investments, Alexandria Venture Investments.
Will IgGenix IPO soon?
No public IPO plans have been announced for IgGenix.
How can I track IgGenix secondary market activity?
Caplight tracks bids, offers, and trades in IgGenix's shares on secondary markets.